May 8 |
MannKind (MNKD) Beats Q1 Earnings and Revenue Estimates
|
May 8 |
MannKind GAAP EPS of $0.04 beats by $0.01, revenue of $66.26M beats by $5.71M
|
May 8 |
MannKind Corporation Reports 2024 First Quarter Financial Results: Provides Clinical Development Update
|
May 7 |
MannKind Q1 Earnings Preview
|
May 6 |
MannKind Receives U.S. FDA Fast Track Designation for Clofazimine Inhalation Suspension for the Treatment of Nontuberculous Mycobacterial (NTM) Lung Disease
|
May 1 |
MannKind Corporation to Hold 2024 First Quarter Financial Results Conference Call on May 8, 2024
|
Apr 3 |
MannKind Repays Certain Debt Obligations
|
Apr 1 |
MannKind Corporation (NASDAQ:MNKD) down to US$1.2b market cap, but institutional owners may not be as affected after a year of 9.7% returns
|